A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-neive pancreatic adenocarcinoma (PC)

被引：2
|
作者：
Cohen, S. J.
Zalupski, M. M.
Conkling, P.
Nugent, F. W.
Ma, W.
Modiano, M.
Pascual, R. A.
Lee, F.
Wong, L.
Hersh, E.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Virginia Oncol Associates, US Oncol Phase Grp 2, Norfolk, VA USA
[4] Tufts Univ, Sch Med, Lahey Clin Med Ctr, Burlington, MA USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[6] Arizona Clin Res Ctr, Tucson, AZ USA
[7] Michiana Hematol Oncol PC, South Bend, IN USA
[8] Univ New Mexico, Albuquerque, NM 87131 USA
[9] Scott & White Mem Hosp & Clin, Temple, TX USA
[10] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4076
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naive Pancreatic Adenocarcinoma
    Cohen, Steven J.
    Zalupski, Mark M.
    Conkling, Paul
    Nugent, Francis
    Ma, Wen Wee
    Modiano, Manuel
    Pascual, Rolan
    Lee, Fa Chyi
    Wong, Lucas
    Hersh, Evan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 230 - 235
  • [2] Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas.
    Richards, DA
    Oettle, H
    Vervenne, WL
    Saif, MW
    Thomas, JP
    Spitzer, G
    Visseren-Grul, C
    Enas, N
    Weitzman, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 330S - 330S
  • [3] A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer
    Sun, Y.
    Li, Y.
    Qin, S.
    Ma, D.
    Jiao, S. C.
    Yu, S. Y.
    Li, J.
    Liu, D.
    Song, D.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas
    Saif, Muhammad Wasif
    Oettle, H.
    Vervenne, W. L.
    Thomas, J. P.
    Spitzer, G.
    Visseren-Grul, C.
    Enas, N.
    Richards, D. A.
    CANCER JOURNAL, 2009, 15 (04): : 339 - 343
  • [5] Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a Phase 2 trial
    Chiorean, E.
    Dragovich, T.
    Hamm, J.
    Barrios, C. H.
    Gorini, C. F. N.
    Langmuir, V. K.
    Kroll, S.
    Tidmarsh, G. T.
    Colowick, A. B.
    Loehrer, P. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 266 - 266
  • [6] Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
    Kindler, Hedy L.
    Ioka, Tatsuya
    Richel, Dirk J.
    Bennouna, Jaafar
    Letourneau, Richard
    Okusaka, Takuji
    Funakoshi, Akihiro
    Furuse, Junji
    Park, Young Suk
    Ohkawa, Shinichi
    Springett, Gregory M.
    Wasan, Harpreet S.
    Trask, Peter C.
    Bycott, Paul
    Ricart, Alejandro D.
    Kim, Sinil
    Van Cutsem, Eric
    LANCET ONCOLOGY, 2011, 12 (03): : 256 - 262
  • [7] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
    Reni, Michele
    Riess, Hanno
    O'Reilly, Eileen Mary
    Park, Joon Oh
    Hatoum, Hassan
    Saez, Berta Laquente
    Salminen, Tapio
    Oettle, Helmut
    Lopez, Rafael
    Dowden, Scot D.
    Karthaus, Meinolf
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: Preliminary results of a phase 2 trial
    Chiorean, E. G.
    Dragovich, T.
    Hamm, J.
    Barrios, C. H.
    Gorini, C. F.
    Langmuir, V. K.
    Kroll, S.
    Tidmarsh, G. T.
    Colowick, A. B.
    Loehrer, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Goncalves, A.
    Viret, F.
    Francois, E.
    Dahan, L.
    Perrier, H.
    Lamy, R.
    Re, D.
    Largillier, R.
    Gasmi, M.
    Tchiknavorian, X.
    Turrini, O.
    Moureau-Zabotto, L.
    Delpero, J.
    Viens, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345